Partnership expands spectrum of Secarna’s capabilities for the development of targeted ASOs beyond antibodies and sugar molecules

Orano Med SAS, “Orano Med”, a biotechnology company developing Lead-212 Targeted Alpha Therapy against cancer, and Orbit Discovery Ltd, “Orbit”, a leader in the discovery of therapeutic peptide hits, today announced that they have entered into a collaboration to discover specific Peptide Receptor Radionuclide Therapies against cancer cells and advance the development of novel radiopharmaceuticals. Under the terms of the agreement, Orbit will deploy its bead-based peptide display engine to discover peptide leads specific to targets related to specific tumours.

Evergreen Discovery (Evergreen), a leading radiopharmaceutical drug development company with a focus on the treatment and diagnosis of cancer, and Orbit Discovery Ltd (Orbit), a leader in the discovery of therapeutic peptide hits, announced today that they have entered into a collaboration to identify specific cell targeting peptides and advance the development of novel radiopharmaceuticals. The agreement covers activities ranging from designing peptide libraries, hit identification and hit validation to confirm cell surface binding properties.

Orbit Discovery Limited (Orbit), a leader in the discovery of therapeutic peptide hits, today announced it has entered into a multi target Research Agreement with Endevica Bio Inc., (Endevica), a company dedicated to creating first-in-class therapeutics for cachexia caused by cancer and other chronic conditions, with its lead compound having proven safe and well-tolerated in its Phase 1 trials. The collaboration aims to accelerate Endevica’s development of advanced G-protein coupled receptor (GPCR)-targeting therapeutics on receptor sets both novel and complimentary to its lead compound.

Oxford, UK, 05 January 2023: Orbit Discovery Limited (Orbit), a leader in the discovery of therapeutic peptide hits, today announced it has entered into a Master Service Agreement with SanegeneBio Inc., (Sanegene), a start-up company dedicated to developing novel RNAi-based medicines. The focus of the collaboration is to identify tissue-specific delivery of a wide range of RNA therapeutics to efficiently knock down disease-causing genes.

Project will use microfluidic technology to improve efficiency of peptide therapeutics discovery for challenging drug targets

Orbit Discovery (Orbit), a ground-breaking peptide discovery company is pleased to announce the commencement of a partnership with WuXi AppTec, a leading global provider of R&D and manufacturing services that enable the global pharmaceutical and healthcare industry.

Orbit Discovery Ltd., (“Orbit”), a privately held biopharmaceutical company focused on discovering candidate peptide therapeutics harnessing proprietary affinity and cell-based functional screening platforms, today announced that it has raised $7.6 million in funding.

Orbit Discovery Ltd (“Orbit”), a biopharmaceutical company focused on discovering candidate peptide therapeutics using high throughput microfluidic platforms, has announced the appointment of Dr Neil Butt as Chief Executive Officer.

Orbit Discovery, an Oxford, UK-based biotech company developing an industry-leading peptide discovery platform, are pleased to announce that Dr Mario Polywka has joined their board as a non-executive director.